Physician profile
Julia Riel
NPI 1518493709
$1,815.96
in general payments reported to CMS, 2019-2025
12 companies · $405 in 2025
The $405 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $129 · 2024: $1,282 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,621 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,620.98 |
| Education | $194.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $866.59 | 2023-2025 | Tremfya, Simponi, Stelara |
| Lilly USA, LLC | $252.71 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $165.94 | 2024 | Sotyktu |
| Abbvie INC. | $161.49 | 2023-2025 | |
| Ucb, INC. | $100.70 | 2024 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $72.60 | 2023 | |
| Amgen INC. | $58.87 | 2024 | Otezla |
| Incyte Corporation | $41.32 | 2024 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.46 | 2024 | Spevigo |
| Sandoz INC. | $23.95 | 2023 | Hyrimoz |
| Dermavant Sciences, INC. | $23.78 | 2024 | Vtama |
| Genzyme Corporation | $19.55 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Riel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.